Advertisement
UK markets open in 32 minutes

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,167.07
    +338.14 (+2.01%)
     

  • CRUDE OIL

    83.51
    +0.15 (+0.18%)
     

  • GOLD FUTURES

    2,341.40
    -0.70 (-0.03%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • Bitcoin GBP

    53,543.65
    +6.52 (+0.01%)
     

  • CMC Crypto 200

    1,415.06
    -9.04 (-0.63%)
     

  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Shire eating disorder drug gets U.S. priority review

Reuters - UK Focus

LONDON, Sept 15 (Reuters) - Shire (LSE: SHP.L - news) 's hyperactivity drug Vyvanse will get a priority review in the United States as a potential treatment for binge eating disorder, showing a willingness by U.S. regulators to consider novel ways to fight eating problems.

The U.S. Food and Drug Administration last week approved Orexigen Therapeutics (NasdaqGS: OREX - news) 's long-awaited obesity pill Contrave and an advisory panel also backed Novo Nordisk (Other OTC: NONOF - news) 's injectable drug liraglutide for weight loss.

Dublin-based Shire, which is being acquired by U.S. drugmaker AbbVie (Xetra: 4AB.DE - news) , said on Monday that the FDA was expected to give its decision on the new use of Vyvanse by February 2015.

Vyvanse is currently only approved for Attention-Deficit Hyperactivity Disorder.

(Reporting by Ben Hirschler; editing by Susan Thomas)